- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03875313
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Winship Cancer Institute of Emory University
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
New York
-
New York, New York, United States, 10032
- Columbia University
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson
-
San Antonio, Texas, United States, 78229
- South Texas Accelerated Research Therapeutics, LLC
-
-
Utah
-
Salt Lake City, Utah, United States, 20000
- Huntsman Cancer Institute
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
(Part 1)
-Documented incurable/locally advanced or metastatic solid tumors that have either relapsed or are refractory or intolerant to standard therapies of proven clinical benefit.
(Part 2) Meets 1 of the 3 defined cohorts:
- Cohort 1: Documented incurable/locally advanced or metastatic ccRCC
- Cohort 2: Documented incurable/locally advanced or metastatic defined as ER, PR negative (<1%) and HER2 negative (immunohistochemistry 0 to 1+ or fluorescence in situ hybridization [FISH] negative)
- Cohort 3: incurable/locally advanced or metastatic CRC
For both Parts 1 & 2:
- Recovery to baseline or ≤ Grade 1 Common Terminology Criteria for Adverse Events (CTCAE) v.5.0 from toxicities related to the prior therapy
- Adequate renal, hepatic, and hematological function
- Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 evaluable disease (Part 1) or measurable disease (Part 2)
- Ability to provide written consent in accordance with federal, local and institutional guidelines
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
Exclusion Criteria for both Parts 1 & 2:
- Prior treatment with CB-839 or a PARP inhibitor
- Unable to received oral medications
- Active and/or untreated central nervous system metastasis. Patients with treated brain metastases must have (1) documented radiographic stability of at least 4 weeks duration demonstrated on baseline central nervous system (CNS) imaging prior to study treatment and (2) be symptomatically stable and off steroids for at least 2 weeks before administration of any study treatment.
- Major surgery within 28 days prior to first dose of study drug
- Receipt of any anticancer therapy within the following windows: small molecule tyrosine kinase inhibitor therapy (including investigational) within the prior 2 weeks or 5 half-lives prior to C1D1, whichever is longer; any type of anti-cancer antibody or cytotoxic chemotherapy within 4 weeks prior to C1D1; radiation therapy for bone metastasis within 2 weeks prior or any other external radiation therapy within 4 weeks prior to C1D1; patients with clinically relevant ongoing complications from prior radiation therapy are not eligible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 600 mg CB-839 + 1 mg Talazoparib
600 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with advanced or metastatic solid tumors.
|
CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.
Other Names:
Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.
Other Names:
|
Experimental: 800 mg CB-839 + 1 mg Talazoparib: ccRCC
800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with incurable/locally advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received ≥ 2 prior systemic regimens including ≥ 1 vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI) therapy.
|
CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.
Other Names:
Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.
Other Names:
|
Experimental: 800 mg CB-839 + 1 mg Talazoparib: TNBC
800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with incurable/locally advanced or metastatic triple-negative breast cancer (TNBC) estrogen receptor (ER)-, progesterone receptor (PR)-, and human epidermal growth factor receptor 2 (HER2)-negative who received ≥ 1 prior line of cytotoxic chemotherapy with no prior poly adenosine diphosphate ribose polymerase (PARP) inhibitor therapy for TNBC or platinum-based chemotherapy for metastatic TNBC.
|
CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.
Other Names:
Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.
Other Names:
|
Experimental: 800 mg CB-839 + 1 mg Talazoparib: CRC
800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with with incurable/locally advanced or metastatic colorectal cancer (CRC) who received appropriate oxaliplatin or irinotecan- and fluorouracil (5-FU)-based chemotherapy with or without bevacizumab.
|
CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.
Other Names:
Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.
Other Names:
|
Experimental: 800 mg CB-839 + 1 mg Talazoparib: Other Histology
800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with other tumor types (prostate, urinary bladder, pancreas, and stomach).
|
CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.
Other Names:
Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Excluding Deaths Due to Disease Progression
Time Frame: Start of treatment to 28 days post treatment; mean overall duration of talazoparib exposure was 88.7 days.
|
AEs were grades as assessed by CTCAE v 5.0. A TEAE is defined as any AE occurring on or after the first dose of study drug, or existing events that worsened after the first dose during the study, up to 28 days after the last dose. An AE is considered "related" if the investigator assessed the relationship as "possibly related" or "probably related." Disease progression includes events in the preferred terms of disease progression and malignant neoplasm progression. Grade 5 disease progression events are excluded from this table. |
Start of treatment to 28 days post treatment; mean overall duration of talazoparib exposure was 88.7 days.
|
Number of Participants With Laboratory Abnormalities (Hematology, Clinical Chemistry) at More Than 1 Clinic Visit
Time Frame: Hematology: screening, cycle 1 day 1, cycle 1 day 15, cycle 2 day 1, end of treatment (EOT). Clinical chemistry parameters: screening, cycle 1 day 1, cycle 1 day 8, cycle 1 day 15, cycle 1 day 22, cycle 2 day 1, cycle 2 day 15, EOT.
|
Hematology parameters conducted included red blood cell (RBC) count, hematocrit, hemoglobin, mean corpuscular volume (MCV), platelet count, white blood cell (WBC) count, neutrophils, lymphocytes, monocytes, eosinophils, and basophils, performed at the discretion of the investigator.
Clinical chemistry parameters included aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, direct bilirubin, albumin, total protein, blood urea nitrogen (BUN), creatinine, sodium, potassium, chloride, calcium, carbon dioxide, glucose, and lactate dehydrogenase (LDH), performed at the discretion of the investigator.
|
Hematology: screening, cycle 1 day 1, cycle 1 day 15, cycle 2 day 1, end of treatment (EOT). Clinical chemistry parameters: screening, cycle 1 day 1, cycle 1 day 8, cycle 1 day 15, cycle 1 day 22, cycle 2 day 1, cycle 2 day 15, EOT.
|
Number of Participants With Dose-Limiting Toxicities (DLTs)
Time Frame: During Cycle 1 on Days 1 through 28, inclusive
|
A DLT was defined as an AE determined by the investigator to be possibly or probably related to study drug that also was:
|
During Cycle 1 on Days 1 through 28, inclusive
|
Overall Response Rate (ORR)
Time Frame: Maximum duration of follow-up for ORR was 12.9 months.
|
ORR was defined by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 as the percentage of participants with documented complete response (CR) or partial response (PR) since the date of treatment initiation.
CR=Disappearance of all target lesions.
Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.
PR=At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Stable disease must have been a minimum of 51 days from date of treatment initiation.
Exact binomial confidence intervals (Clopper Pearson).
|
Maximum duration of follow-up for ORR was 12.9 months.
|
Confirmed ORR (cORR)
Time Frame: Maximum duration of follow-up for cORR was 12.9 months.
|
Overall Response Rate is defined by RECIST v1.1 as the percentage of participants with documented confirmed CR or confirmed PR since the date of treatment initiation.
CR=Disappearance of all target lesions.
Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.
PR=At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
CR or PR must have been sustained a minimum of 28 days when confirmation was reported.
Stable disease must have been a minimum of 51 days from date of treatment initiation.
Exact binomial confidence intervals (Clopper Pearson).
|
Maximum duration of follow-up for cORR was 12.9 months.
|
Clinical Benefit Rate (CBR)
Time Frame: Maximum duration of follow-up for CBR was 12.9 months.
|
Clinical Benefit Rate is defined by RECIST v1.1 as the percentage of participants with documented CR, PR, or stable disease (SD) since the date of treatment initiation.
CR=Disappearance of all target lesions.
Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.
PR=At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
CR or PR must have been sustained a minimum of 28 days when confirmation was reported.
SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.
SD must have been a minimum of 102 days from date of treatment initiation and documented on at least 2 consecutive post-baseline scans.
Exact binomial confidence intervals (Clopper Pearson).
|
Maximum duration of follow-up for CBR was 12.9 months.
|
Progression-Free Survival (PFS)
Time Frame: Maximum duration of follow-up for PFS was 12.9 months.
|
PFS was defined as the time from treatment initiation to the date of documented disease progression (PD) within 2 consecutive scheduled radiographic disease assessments or death for any cause, whichever occurs first.
PD: ≥ 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).
In addition, the sum must also demonstrate an absolute increase of ≥ 5 mm.
(The appearance of one or more new lesions is also considered progression).
Participants with no documentation of PD or death on-study, PD or death occurs after missing 2 consecutive scheduled radiographic disease assessments, or new anti-cancer therapy were censored at the date of last available tumor assessment.
Participants missing baseline disease assessments were censored at the date of first dose.
Kaplan-Meier product-limit estimates.
Brookmeyer-Crowley methodology for a non-parametric 95% CI was used.
|
Maximum duration of follow-up for PFS was 12.9 months.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Sam Whiting, MD, PhD, Calithera Biosciences, Inc
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Kidney Neoplasms
- Breast Neoplasms
- Carcinoma, Renal Cell
- Triple Negative Breast Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Poly(ADP-ribose) Polymerase Inhibitors
- Talazoparib
Other Study ID Numbers
- CX-839-011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clear Cell Renal Cell Carcinoma
-
Celldex TherapeuticsTerminatedKidney Neoplasms | Metastatic Renal Cell Carcinoma | Ovarian Clear Cell Carcinoma | Papillary Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) | Clear-cell Renal Cell CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Guru SonpavdePfizer; Hoosier Cancer Research NetworkWithdrawnKidney Cancer | Clear-cell Renal Cell Carcinoma | RCC | Clear-cell Kidney CarcinomaUnited States
-
Peloton Therapeutics, Inc.Active, not recruitingA Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)Kidney Cancer | Clear Cell Renal Cell Carcinoma | Glioblastoma | Solid Tumor | Glioblastoma Multiforme | Advanced Solid Tumors | GBM | Solid Tumor, Adult | Solid Carcinoma | Glioblastoma, Adult | ccRCC | RCC, Clear Cell Adenocarcinoma | RCC | Renal Cell Carcinoma, Metastatic | Renal Cell Carcinoma Recurrent | Renal Cell...
-
Queen Mary University of LondonAstraZeneca; Vall d'Hebron Institute of OncologyActive, not recruitingRenal Clear Cell Carcinoma | Renal Papillary Cell CarcinomaUnited Kingdom
-
AmgenCompletedRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell AdenocarcinomaFrance, United States, Germany
-
Association Pour La Recherche des Thérapeutiques...CompletedClear-cell Metastatic Renal Cell Carcinoma | Clear-cell Renal CarcinomaFrance
-
University of WashingtonMerck Sharp & Dohme LLC; Prometheus LaboratoriesTerminatedMetastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Advanced Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell CancerUnited States
-
Telix International Pty LtdGrand Pharmaceutical (China) Co., Ltd.CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Cancer | Suspected Recurrent Renal Clear Cell CarcinomaChina
-
Mabwell (Shanghai) Bioscience Co., Ltd.Not yet recruitingAdvanced Clear Cell Renal Cell Carcinoma
Clinical Trials on CB-839
-
Calithera Biosciences, IncCompletedHealthy VolunteersUnited States
-
Calithera Biosciences, IncCompletedRenal Cell Carcinoma | Non Small Cell Lung Cancer | Mesothelioma | Solid Tumors | Triple-Negative Breast Cancer | Fumarate Hydratase (FH)-Deficient Tumors | Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST) | Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Leptomeningeal Neoplasm | Recurrent Lung Non-Small Cell CarcinomaUnited States
-
Calithera Biosciences, IncCompletedAcute Myeloid Leukemia (AML) | Acute Lymphocytic Leukemia (ALL)United States
-
Calithera Biosciences, IncCompletedMetastatic Renal Cell Carcinoma | Advanced Renal Cell CarcinomaUnited States, United Kingdom, Australia, France, Italy, Germany, Spain, New Zealand
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedChronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Acute Myeloid Leukemia With Multilineage Dysplasia | Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Blasts 20-30 Percent of Peripheral Blood White Cells | IPSS Risk Category Intermediate-2United States
-
David BajorActive, not recruitingCB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal CancerColorectal Cancer | Rectal Cancer | Solid Tumor | Colon CancerUnited States
-
Tallikut Pharmaceuticals, Inc.Completed
-
Calithera Biosciences, IncCompletedMultiple Myeloma | Non-Hodgkin's Lymphoma (NHL) | Waldenstrom's Macroglobulinemia (WM) | Other B-cell NHL Subtypes, Including WM | T-cell NHLUnited States
-
Massachusetts General HospitalPfizer; Prostate Cancer Foundation; Calithera Biosciences, IncNot yet recruiting